Goldman Sachs’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.9M | Sell |
385,869
-33,365
| -8% | -$1.2M | ﹤0.01% | 2027 |
|
|
2025
Q1 | $13.1M | Sell |
419,234
-146,917
| -26% | -$4.57M | ﹤0.01% | 2028 |
|
|
2024
Q4 | $14.4M | Buy |
566,151
+95,732
| +20% | +$2.44M | ﹤0.01% | 2044 |
|
|
2024
Q3 | $13.3M | Buy |
470,419
+151,237
| +47% | +$4.28M | ﹤0.01% | 2037 |
|
|
2024
Q2 | $8.42M | Sell |
319,182
-283,806
| -47% | -$7.48M | ﹤0.01% | 2231 |
|
|
2024
Q1 | $18.3M | Sell |
602,988
-2,266,558
| -79% | -$68.8M | ﹤0.01% | 1611 |
|
|
2023
Q4 | $80.6M | Sell |
2,869,546
-1,340,649
| -32% | -$37.7M | 0.01% | 750 |
|
|
2023
Q3 | $114M | Buy |
4,210,195
+563,139
| +15% | +$15.3M | 0.02% | 561 |
|
|
2023
Q2 | $112M | Buy |
3,647,056
+1,343,711
| +58% | +$41.3M | 0.02% | 571 |
|
|
2023
Q1 | $83M | Buy |
2,303,345
+1,081,886
| +89% | +$39M | 0.02% | 676 |
|
|
2022
Q4 | $48.3M | Sell |
1,221,459
-155,246
| -11% | -$6.14M | 0.01% | 999 |
|
|
2022
Q3 | $55.3M | Buy |
1,376,705
+390,178
| +40% | +$15.7M | 0.01% | 917 |
|
|
2022
Q2 | $41.5M | Sell |
986,527
-401,103
| -29% | -$16.9M | 0.01% | 1075 |
|
|
2022
Q1 | $54.1M | Buy |
1,387,630
+82,110
| +6% | +$3.2M | 0.01% | 1032 |
|
|
2021
Q4 | $52M | Buy |
1,305,520
+408,117
| +45% | +$16.3M | 0.01% | 1095 |
|
|
2021
Q3 | $32.4M | Sell |
897,403
-66,698
| -7% | -$2.41M | 0.01% | 1381 |
|
|
2021
Q2 | $39.5M | Buy |
964,101
+571,931
| +146% | +$23.4M | 0.01% | 1244 |
|
|
2021
Q1 | $17.1M | Sell |
392,170
-135,590
| -26% | -$5.91M | ﹤0.01% | 1786 |
|
|
2020
Q4 | $26.4M | Buy |
527,760
+351,857
| +200% | +$17.6M | 0.01% | 1365 |
|
|
2020
Q3 | $7.4M | Buy |
175,903
+145,500
| +479% | +$6.12M | ﹤0.01% | 2144 |
|
|
2020
Q2 | $1.48M | Buy |
+30,403
| New | +$1.48M | ﹤0.01% | 3008 |
|